BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11914880)

  • 21. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
    Spaepen K; Mortelmans L
    Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison].
    Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M
    Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDG-PET/CT in re-staging of patients with lymphoma.
    Freudenberg LS; Antoch G; Schütt P; Beyer T; Jentzen W; Müller SP; Görges R; Nowrousian MR; Bockisch A; Debatin JF
    Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):325-9. PubMed ID: 14647988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma.
    Schiepers C; Filmont JE; Czernin J
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S82-8. PubMed ID: 12719922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood.
    Sioka C
    Eur J Pediatr; 2013 Jun; 172(6):733-8. PubMed ID: 23559330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positron emission tomography in the management of lymphomas.
    O'Doherty MJ; Macdonald EA; Barrington SF; Mikhaeel NG; Schey S
    Clin Oncol (R Coll Radiol); 2002 Oct; 14(5):415-26. PubMed ID: 12555882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Positron-emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment].
    Mainolfi C; Maurea S; Varrella P; Alaia C; Imparato C; Alfano B; Abate G; Bazzicalupo L
    Radiol Med; 1998; 95(1-2):98-104. PubMed ID: 9636735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment.
    Bar-Shalom R; Mor M; Yefremov N; Goldsmith SJ
    Semin Nucl Med; 2001 Jul; 31(3):177-90. PubMed ID: 11430525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients.
    Van Den Bossche B; Lambert B; De Winter F; Kolindou A; Dierckx RA; Noens L; Van De Wiele C
    Nucl Med Commun; 2002 Nov; 23(11):1079-83. PubMed ID: 12411836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?
    Schaefer NG; Hany TF; Taverna C; Seifert B; Stumpe KD; von Schulthess GK; Goerres GW
    Radiology; 2004 Sep; 232(3):823-9. PubMed ID: 15273335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Value of positron emission tomography in treatment of lymphoma patients].
    Kuwert T
    Strahlenther Onkol; 2001 Mar; 177(3):160-1. PubMed ID: 11285774
    [No Abstract]   [Full Text] [Related]  

  • 32. 18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence?
    Juweid ME
    J Nucl Med; 2008 Jan; 49(1):9-12. PubMed ID: 18077522
    [No Abstract]   [Full Text] [Related]  

  • 33. 18F-FDG PET in children with lymphomas.
    Depas G; De Barsy C; Jerusalem G; Hoyoux C; Dresse MF; Fassotte MF; Paquet N; Foidart J; Rigo P; Hustinx R
    Eur J Nucl Med Mol Imaging; 2005 Jan; 32(1):31-8. PubMed ID: 15605288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of FDG-PET imaging in the management of lymphoma.
    Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
    Cheson BD; Fisher RI; Barrington SF; Cavalli F; Schwartz LH; Zucca E; Lister TA; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
    J Clin Oncol; 2014 Sep; 32(27):3059-68. PubMed ID: 25113753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
    Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma].
    Thill R; Neuerburg J; Fabry U; Cremerius U; Wagenknecht G; Hellwig D; Osieka R; Günther R; Büll U
    Nuklearmedizin; 1997 Oct; 36(7):234-9. PubMed ID: 9441282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of Lymphoma Therapy Using (18)F-FDG PET.
    Lowe VJ; Wiseman GA
    J Nucl Med; 2002 Aug; 43(8):1028-30. PubMed ID: 12163627
    [No Abstract]   [Full Text] [Related]  

  • 40. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.